Sign In
Buy IOVA
$3.79
-0.310 (-7.56%)
At Close: Jun 03, 2026
Watch These 5 Drug Stocks for Q1 Earnings: Beat or Miss?
11:41am, Monday, 06'th May 2024
Let us look at five drug, generic companies, PRGO, IOVA, VTRS, TEVA and ACAD, which are gearing up for their earnings release this week.
Iovance (IOVA) Gears Up for Q1 Earnings: Here's What to Expect
11:01am, Monday, 06'th May 2024
Investors' focus will likely be on Iovance's (IOVA) progress with its ongoing commercial launch for a recently approved melanoma drug. An update is also expected on its early-stage pipeline.
Iovance (IOVA) stock price could jump by 30% after earnings
09:28am, Monday, 06'th May 2024
Iovance Biotherapeutics (NASDAQ: IOVA) stock price has rebounded sharply in the past few days as traders wait for the upcoming financial results. It rose by almost 6% on Friday and by over 3% on Monda
Got $500? These Hot Growth Stocks Are Screaming Buys Right Now
07:01pm, Sunday, 05'th May 2024
Rocket Lab USA is in the right place at the right time with the right solution. The amount of digital data is exploding, and Confluent helps companies get a handle on this challenge.
Iovance Biotherapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Thursday, May 9, 2024
06:01am, Wednesday, 01'st May 2024
SAN CARLOS, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infi
Iovance Biotherapeutics to Present at Upcoming Conferences
06:01am, Tuesday, 30'th Apr 2024
SAN CARLOS, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor in
Where Will Iovance Biotherapeutics Stock Be in 5 Years?
02:44pm, Sunday, 28'th Apr 2024
Iovance Biotherapeutics recently obtained approval for Amtagvi. The cell therapy has the potential to become a blockbuster, and Iovance has many other trials ongoing.
The Top 3 Biotech Stocks to Buy in April 2024
07:00am, Saturday, 27'th Apr 2024
Biotech stocks are notorious for being some of the most volatile and unpredictable on the market. With clinical trials and FDA approvals creating potential leaps or falls in what seems like an instant
3 Millionaire-Maker Biotech Stocks
10:30am, Thursday, 25'th Apr 2024
Oncology's future prominently features the kind of autoimmune R&D work that Iovance is doing. Helped by new technology, Recursion is using artificial intelligence to develop new drugs.
Iovance Biotherapeutics to Present Clinical and Translational Data at 2024 ASCO Annual Meeting
04:01pm, Wednesday, 24'th Apr 2024
Oral Presentation of Updated Results of IOV-COM-202 Cohort 1A of Lifileucel plus Pembrolizumab in Advanced Frontline Melanoma Oral Presentation of Updated Results of IOV-COM-202 Cohort 1A of Lifileuce
These Biotech Stocks Could Soar 120% and 295%, According to Wall Street
05:08am, Sunday, 21'st Apr 2024
Bull markets favor growth stocks, and that means many biotech players could benefit. Wall Street believes in the potential of these two biotech innovators.
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
05:15pm, Friday, 19'th Apr 2024
SAN CARLOS, Calif., April 19, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) (“Iovance” or the “Company”), a biotechnology company focused on innovating, developing, and
Is Iovance Biotherapeutics Stock a Buy Now?
09:45am, Wednesday, 17'th Apr 2024
Iovance Biotherapeutics has a novel approach to developing cancer medicines. The small biotech recently earned approval for an important product.
The Top 5 Analysts Ranked by Marketbeat and Stocks They Cover
07:01am, Tuesday, 09'th Apr 2024
Marketbeat's many investor tools include analysts' rankings and sentiment trackers. These tools help investors and traders gauge market sentiment, showing trends and changes, updated revisions, and ne
Iovance Biotherapeutics: Riding The Favorable Moment Could Bring Excellent Results
06:05am, Tuesday, 09'th Apr 2024
Iovance Biotherapeutics is experiencing a favorable moment following FDA approval for its melanoma drug Amtagvi and a successful underwritten offering. The company has developed its own production cap
